Progress toward noninvasive prenatal diagnosis.
نویسنده
چکیده
For decades, noninvasive analysis of the fetal genotype has been the holy grail of the field of prenatal diagnosis. Noninvasive prenatal diagnosis (NIPD) would use a sample source other than amniocentesis or chorionic villus sampling. The focus has been primarily on the use of maternal blood samples, with less attention given to the possibility of recovering fetal cells from maternal cervical samples (as would be collected for cervical cancer screening). The initial efforts focused on the presence of fetal cells in the maternal circulation, and evidence indicated as early as 1979 that fetal cells could be recovered via fluorescence-activated cell sorting. The elegant strategy of using antibodies to paternal HLA antigens to identify fetal cells was demonstrated. Attempts to recover fetal cells focused for a time on fetal nucleated red blood cells via analysis with fluorescence in situ hybridization and the PCR, but the disappointing results led to skepticism that NIPD would ever become a reality. By 1996 there were reports of tumor DNA detected in the plasma of cancer patients, and Lo et al. first reported in 1997 the presence of fetal DNA in maternal plasma. The use of fetal DNA in the plasma has important advantages over the use of fetal cells in that fetal DNA can be obtained consistently in virtually 100% of pregnancies, whereas fetal cells are recovered much less consistently. In recent years, the use of fetal DNA in maternal plasma to detect fetal sex has become a well-established clinical test [see references in Lo et al. (1 ) for background on this test and other details]. In fact, determining whether any genotype present in the father but not the mother has been transmitted to the fetus is relatively straightforward. This approach has been used to determine whether a fetus is Rh negative or positive in the context of the risk for Rh incompatibility. Similarly, a fetus at risk of inheriting a dominant mutation (e.g., polyposis coli) from the father can be tested for the presence of the mutation. In the case of recessive disorders (e.g., cystic fibrosis) in which the parents have different mutations, one can determine whether the fetus has inherited the paternal mutation. Two newer technologies have greatly altered the prospects for NIPD. One technology is chromosomal microarray analysis, which has opened the possibility of detecting a wide range of disease-causing copy number variants (CNVs), such as those causing DiGeorge, Williams, and Smith–Magenis syndromes. This technology expands the emphasis on NIPD from detection of trisomy 21 alone to broader detection of tens and even hundreds of serious disabilities caused by microdeletions or microduplications. Array comparative genomic hybridization (CGH) enables the detection of CNVs and aneuploidy in single blastomeres. Thus, if single fetal cells could be recovered reliably from maternal blood or the cervix, NIPD could potentially be used to detect all forms of aneuploidy and most disease-causing CNVs. If such cells could be obtained, testing could be implemented with current technology and at costs similar to those currently for invasive prenatal diagnosis. The second new technology is next-generation (Next-Gen) sequencing. This term refers to the many instruments and platforms that permit the collection of enormous amounts of DNA sequence data at lower costs. A recent report by Lo et al. (1 ) applied Next-Gen sequencing to the analysis of fetal DNA in maternal plasma and provided evidence that NIPD is closer at hand than ever. Although the report successfully analyzed a single pregnancy at risk for -thalassemia, the findings have much broader implications. The investigators sequenced plasma DNA to provide 65-fold coverage, meaning that the amount of sequencing was equivalent to that of 65 haploid genomes. They used single-nucleotide polymorphism data from both parents in an elegant computational way to distinguish fetal sequence reads from maternal reads to the extent possible. Importantly, they demonstrated for the first time that the entire fetal genome was represented in a uniform manner, with close to 11% fetal sequence and 89% maternal sequence for each chromosome. This result is equivalent to about 7-fold coverage of the fetal haploid genome or about 3.5-fold coverage of each diploid allele. The authors demonstrated the feasibility of deciphering the entire genome of the fetus from a 1 Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX. * Address correspondence to the author at: Department of Molecular and Human Genetics, Baylor College of Medicine, One Baylor Plaza, BCM225, Houston, TX 77030. Fax 713-798-7773; e-mail [email protected]. Received March 30, 2011; accepted March 31, 2011. Previously published online at DOI: 10.1373/clinchem.2011.165563 2 Nonstandard abbreviations: NIPD, noninvasive prenatal diagnosis; CNV, copy number variant; CGH, comparative genomic hybridization; Next-Gen, nextgeneration (sequencing). Clinical Chemistry 57:6 000 – 000 (2011) Perspectives
منابع مشابه
Comparison of noninvasive prenatal testing of cell‐free DNA in maternal blood and amniocentesis for evaluation of aneuploidy
Background: The aim of this study was to compare noninvasive prenatal testing (NIPT) of cell‐free DNA in maternal blood and amniocentesis in the diagnosis of aneuploidy. This study was designed to evaluate sensitivity, specificity, accuracy, positive predictive value and negative predictive value of NIPT for detection of aneuploidies compared gold standard test of amniocentesis. Materials and m...
متن کاملNoninvasive prenatal testing for aneuploidy-ready for prime time?
t u e t Noninvasive prenatal diagnosis using cell-free fetal DNA in the maternal plasma is moving into routine clinical practice for some indications. Here we discuss exciting developments in noninvasive prenatal diagnosis for aneuploidy afforded by recent publications, including 2 papers published in this journal, and highlight some of the issues that need to be considered before these tests c...
متن کاملNoninvasive fetal genome sequencing: a primer.
We recently demonstrated whole genome sequencing of a human fetus using only parental DNA samples and plasma from the pregnant mother. This proof-of-concept study demonstrated how samples obtained noninvasively in the first or second trimester can be analyzed to yield a highly accurate and substantially complete genetic profile of the fetus, including both inherited and de novo variation. Here,...
متن کاملSystematic review of noninvasive prenatal diagnosis for abnormal chromosome genetic diseases using free fetal DNA in maternal plasma.
We evaluated the system accuracy of noninvasive prenatal diagnosis for abnormal chromosome genetic diseases using cell-free fetal DNA in maternal plasma. Previous studies were searched in the MEDLINE database using the following keywords: "prenatal" and "aneuploidy" and "noninvasive or non-invasive" and "maternal". Identified studies were filtered using a QUADAS instrument. Four studies were id...
متن کاملMeDIP Real-Time qPCR has the Potential for Noninvasive Prenatal Screening of Fetal Trisomy 21
This study aimed to verify the reliability of the 7 tissue differentially methylated regions used in the methylated DNA immunoprecipitation (MeDIP) real-time quantitative polymerase chain reaction (real-time qPCR) based approach of fetal DNA in maternal blood to diagnosis of fetal trisomy 21. Forty pregnant women with high risk pregnancy who were referred after first or second trimester screeni...
متن کاملNoninvasive Prenatal Detection for Pathogenic CNVs: The Application in α-Thalassemia
BACKGROUND The discovery of cell free fetal DNA (cff-DNA) in maternal plasma has brought new insight for noninvasive prenatal diagnosis. Combining with the rapidly developed massively parallel sequencing technology, noninvasive prenatal detection of chromosome aneuploidy and single base variation has been successfully validated. However, few studies discussed the possibility of noninvasive path...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Clinical chemistry
دوره 57 6 شماره
صفحات -
تاریخ انتشار 2011